Analysts expect Tricida Inc (NASDAQ:TCDA) to post earnings per share of ($0.90) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tricida’s earnings. The highest EPS estimate is ($0.83) and the lowest is ($0.96). Tricida reported earnings per share of ($0.66) during the same quarter last year, which suggests a negative year-over-year growth rate of 36.4%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Tricida will report full year earnings of ($3.54) per share for the current fiscal year, with EPS estimates ranging from ($3.67) to ($3.40). For the next financial year, analysts forecast that the company will report earnings of ($3.64) per share, with EPS estimates ranging from ($3.93) to ($3.35). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Tricida.

Tricida (NASDAQ:TCDA) last released its earnings results on Thursday, August 8th. The company reported ($0.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.12.

TCDA has been the topic of a number of research analyst reports. Zacks Investment Research lowered Tricida from a “hold” rating to a “sell” rating in a report on Wednesday. Cowen reissued a “buy” rating and set a $50.00 price target on shares of Tricida in a report on Thursday, August 8th. Needham & Company LLC set a $50.00 price target on Tricida and gave the company a “buy” rating in a report on Monday. Finally, Goldman Sachs Group initiated coverage on Tricida in a report on Wednesday, June 26th. They set a “buy” rating and a $48.00 price target on the stock.

In related news, Director Robert J. Alpern sold 3,000 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $37.05, for a total value of $111,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gerrit Klaerner sold 4,000 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $31.17, for a total value of $124,680.00. The disclosure for this sale can be found here. Insiders have sold 90,126 shares of company stock valued at $3,218,846 in the last ninety days. Company insiders own 66.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC acquired a new stake in Tricida during the 1st quarter worth about $39,000. Bank of Montreal Can acquired a new stake in Tricida during the 2nd quarter worth about $72,000. Amundi Pioneer Asset Management Inc. acquired a new stake in Tricida during the 4th quarter worth about $99,000. Marshall Wace North America L.P. boosted its position in Tricida by 99.0% during the 1st quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after acquiring an additional 1,289 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its position in Tricida by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,946 shares of the company’s stock worth $140,000 after acquiring an additional 4,644 shares during the period. Institutional investors and hedge funds own 63.12% of the company’s stock.

Shares of TCDA traded up $0.51 during trading hours on Thursday, reaching $32.64. 187,200 shares of the company’s stock traded hands, compared to its average volume of 288,150. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -7.03 and a beta of 0.90. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.30 and a quick ratio of 8.30. Tricida has a twelve month low of $19.43 and a twelve month high of $42.80. The business’s fifty day simple moving average is $33.80 and its two-hundred day simple moving average is $31.36.

About Tricida

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

See Also: Reverse Stock Split

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.